

PRODUCT INFORMATION



KMN-80

Item No. 15435

Issued United States Patent US 9,688,627 and all US and foreign patents pending related to PCT Publ. No. WO 2014/144584.

CAS Registry No.: 1628759-75-0

Formal Name: 7-((R)-2-((3S,4S,E)-3-hydroxy-4-methylnon-1-en-6-yn-1-yl)-5-oxopyrrolidin-1-yl)heptanoic acid

MF: C₂₁H₃₃NO₄


FW: 363.5

Purity: ≥98%

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

KMN-80 is supplied as a crystalline solid. A stock solution may be made by dissolving the KMN-80 in the solvent of choice, which should be purged with an inert gas. KMN-80 is soluble in the organic solvent DMSO at a concentration of approximately 10 mg/ml.

Description

The prostaglandin E receptor 4 (EP₄) is one of four G protein-coupled receptors that mediate the actions of prostaglandin E₂ (PGE₂; Item No. 14010). Binding of PGE₂ to the EP₄ receptor causes an increase in intracellular cyclic AMP, which plays important roles in bone formation and resorption, cancer, and atherosclerosis.¹⁻⁴ KMN-80 is a substituted γ -lactam (pyrrolidinone) derivative of PGE₁ (Item No. 13010) that acts as a selective and potent agonist of EP₄ with an IC₅₀ value of 3 nM (IC₅₀ = 1.4 μ M for EP₃ and > 10 μ M for all other prostanoid receptors).⁵ In functional assays it has been shown to stimulate secreted alkaline phosphatase gene reporter activity in EP₄-transfected HEK293 cells with an EC₅₀ value of 0.19 nM, demonstrating >5,000 and 50,000-fold selectivity against EP₂ and TP, respectively.⁵ KMN-80 can induce the differentiation of bone marrow stem cells from both young and aged rats into osteoblasts *in vitro* (EC₅₀s = 20 and 153 nM, respectively) and exhibits favorable tolerability up to at least 10 μ M, whereas the EP₄ agonist L-902,688 (Item No. 10007712) is highly cytotoxic at similar concentrations in these cells.⁶ KMN-80 has been used to repair calvarial defect in an *in vivo* rat craniomaxillofacial reconstruction model (rate of reduction in defects size equivalent to BMP-2 treated rats) and to promote bone formation in a rat incisor tooth socket model.⁶

References

1. Li, M., Thompson, D.D., and Paralkar, V.M. *Int. Orthop.* **31**, 767-772 (2007).
2. Hawcroft, G., Ko, C.W.S., and Hull, M.A. *Oncogene* **26**, 3006-3019 (2007).
3. Babaev, V.R., Chew, J.D., Ding, L., *et al.* *Cell Metab.* **8**, 492-501 (2008).
4. Konya, V., Marsche, G., Schuligoi, R., *et al.* *Pharmacol. Ther.* **138(3)**, 485-502 (2013).
5. Barrett, S.D., Ciske, F.L., Endres, G.W., *et al.* Novel Potent Lactam Acetylene EP₄ Agonists Stimulate Alkaline Phosphatase Production and Differentiation in Bone Marrow Cells, (2014).
6. O'Malley, J., Uzieblo, A., Germain, B.D., *et al.* Development of a Novel Prostaglandin EP₄ Agonist Which Stimulates Local Bone Formation *in vivo*, (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM